Jo Dae-Sik, Lee Seung-Hyun
Department of Pediatrics, Wonkwang University College of Medicine, Iksan 54538, Republic of Korea.
Children (Basel). 2023 Jan 27;10(2):228. doi: 10.3390/children10020228.
Methotrexate (MTX), a folate antagonist, is used in various fields, including malignancies and rheumatoid or inflammatory autoimmune diseases. MTX is used for the non-surgical treatment of ectopic pregnancies and the elective termination of pregnancy. The teratogenic effects of MTX have been recognized since the 1960s. Fetal methotrexate syndrome (FMS) was established based on the study of congenital anomalies. Generally, there is a risk of FMS when MTX is used between four and six weeks after conception. Here, we reviewed the literature regarding MTX usage and described a case of FMS that was born with a rare anomaly, such as tibial hemimelia, in a mother who had received MTX 4 months before conception for the management of an ectopic pregnancy.
甲氨蝶呤（MTX）是一种叶酸拮抗剂，用于包括恶性肿瘤以及类风湿性或炎性自身免疫性疾病等各个领域。MTX用于异位妊娠的非手术治疗以及选择性终止妊娠。自20世纪60年代以来，MTX的致畸作用就已得到公认。胎儿甲氨蝶呤综合征（FMS）是基于对先天性异常的研究而确立的。一般来说，在受孕后4至6周使用MTX时存在FMS风险。在此，我们回顾了有关MTX使用的文献，并描述了一例FMS病例，该病例出生时伴有罕见异常，如胫骨半肢畸形，其母亲在受孕前4个月因异位妊娠接受了MTX治疗。
